Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.49 |
| ▸ | DRD2 | P14416 | 9/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14619656 | 0.83 | DRD2 (0.60) | ADRA1ADRD2ADRA1DADRA1BSIGMAR1 | |
| SCHEMBL6711151 | 0.83 | ADRA1A (0.55) | CCR2ADRA1AADRA1DADRA1BADRA2A | |
| SCHEMBL24619896 | 0.80 | DRD2 (0.54) | DRD2SIGMAR1 | |
| SCHEMBL5510931 | 0.78 | DRD2 (0.60) | DRD2 | |
| SCHEMBL6847617 | 0.78 | DRD2 (0.59) | DRD2 | |
| SCHEMBL22699069 | 0.77 | DRD2 (0.54) | DRD2SIGMAR1 | |
| SCHEMBL18947871 | 0.77 | DRD2 (0.54) | DRD2SIGMAR1 | |
| SCHEMBL7665709 | 0.77 | ADRA1D (0.52) | ADRA1ADRD2ADRA1DADRA1BADRA2A | |
| SCHEMBL8254760 | 0.77 | DRD2 (0.64) | DRD2SIGMAR1 | |
| SCHEMBL6700 | 0.76 | DRD2 (0.53) | DRD2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | CCR2 513/4885ADRA1A 224/4885DRD2 271/4885 |
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | CCR2 420/4885ADRA1A 161/4885DRD2 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.